Clinical Trials
2 trialsNCT03660826 2026-06-02
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03941860 2025-05-23
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
National Cancer Institute (NCI)
Phase 3 Completed